MetaCap

Metagenomi Therapeutics Inc. (MGX)

NASDAQ: MGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.565-0.0488 (-7.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MGX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$21.36M
EPS (TTM)
-$2.50
52-week range
0.562 – 1.87
Day range
0.5621 – 0.618
Volume / Avg
274.38K / 163.21K
Beta
—

52-week range

$0.562$1.87

MGX stock today

Shares of Metagenomi Therapeutics (MGX) finished lower on Nov 20 at $0.565, a drop of 7.95% or $0.0488 per share, versus the S&P 500's 3.70% decline. At this level, MGX sits near the bottom of its 52-week range of $0.562 to $1.87: 69.8% below the high, set on Dec 22, 2025 and 0.5% above the low. MGX is down 65.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.6%.

Metagenomi Therapeutics has posted a net loss over the last twelve months (EPS of -$2.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Metagenomi Therapeutics

Company profile

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Jian Irish M.B.A., Ph.D.
Headquarters
EmeryVille, CA
Employees
113
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Metagenomi Therapeutics generated $25.2 million in revenue, down 51.8% from fiscal 2024, the first decline in the 3 years shown. Metagenomi Therapeutics reported a net loss of $87.9 million, compared with a loss of $78.1 million a year earlier. Operating margin was -380.9%.

Metagenomi Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$25.21M$52.30M$44.76M
Growth-51.79%+16.84%—
Net income$-87.87M$-78.06M$-68.25M
EPS (diluted)$-2.36$-2.36$-20.05

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$7.00+1138.94%

  • Strong buy 0
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.56 vs $-0.74
Surprise
+24.32%

MGX news

All MGX news

Metagenomi Therapeutics peers

Health Care sector
MGX peer companies
CompanyPrice% ChgMarket capCompare
CVMCel-Sci Corporation1.21-17.69%$21.28Mvs MGX
EVAXEvaxion A/S ADR2.25+10.84%$20.75Mvs MGX
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs MGX
PTHSPelthos Therapeutics Inc.6.38-8.73%$25.08Mvs MGX
INMBINmune Bio Inc.0.827-7.50%$25.60Mvs MGX
LONALeonaBio Inc.2.02-17.89%$26.41Mvs MGX
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs MGX
ESLAEstrella Immunopharma Inc.0.321-5.70%$14.11Mvs MGX

Indexes, lists and sector

Metagenomi Therapeutics stock FAQ

What is Metagenomi Therapeutics's stock price today?

MGX last traded at $0.565 as of Nov 20, 4:00 PM EST, down 7.95% on the day. Prices are delayed at least 15 minutes.

Who is Metagenomi Therapeutics's CEO?

Dr. Jian Irish M.B.A., Ph.D. is the chief executive officer of Metagenomi Therapeutics Inc., which has about 113 employees.

What is the MGX 52-week high?

The 52-week high for MGX is $1.87 and the 52-week low is $0.562. The stock is currently 69.8% below its high.

Compare MGX